Therapy of Travelers' Diarrhea With Rifaximin on Various Continents
The American Journal of GastroenterologyPublished 1 May 2003
Robert Steffen, David A. Sack, Lise Riopel, Zhi-Dong Jiang, Matius Stürchler, Charles D. Ericsson
Citations142
SJR quartileQ1
SJR score2.34
SNIP2.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Rifaximin is efficacious and safe for treatment of travelers’ diarrhea at daily doses of 600 mg or higher and secondary clinical outcome measures were favorably influenced by the active agent.
Abstract
Rifaximin is efficacious and safe for treatment of travelers' diarrhea at daily doses of 600 mg or higher.
Keywords
Medicine
The Journal of Infectious DiseasesPrevalence of Enteric Pathogens among International Travelers with Diarrhea Acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay)
268 Citations2002Zhi‐Dong Jiang, Brett Lowe +7 more
The frequency of resistance among bacterial enteropathogens to traditional antimicrobial agents was particularly high throughout the study period in all 3 regions.
The LancetRisk and aetiology of diarrhoea at various tourist destinations
211 Citations2000Frank von Sonnenburg, Nadia Tornieporth +6 more
Almost two of three tourists developed traveller's diarrhoea during 2-week stays at high-risk destinations and large differences in infection rates between hotels were seen.
Clinical Infectious DiseasesRifaximin versus Ciprofloxacin for the Treatment of Traveler's Diarrhea: A Randomized, Double‐Blind Clinical Trial
206 Citations2001Herbert L. DuPont, Zhi‐Dong Jiang +8 more
Rifaximin is a safe and effective alternative to ciprofloxacin in the treatment of traveler's diarrhea and has potential to improve clinical improvement during the first 24 hours.
The Journal of Infectious DiseasesTreatment of Traveler's Diarrhea with Ciprofloxacin and Loperamide
153 Citations1992Bruno P. Petruccelli, Gerald S. Murphy +7 more
While not delivering a remarkable therapeutic advantage, loperamide appears to be safe for treatment of non-ETEC causes of traveler's diarrhea.
Annals of Internal MedicineTreatment of Travelers' Diarrhea: Ciprofloxacin plus Loperamide Compared with Ciprofloxacin Alone
125 Citations1991David N. Taylor, José Luis Sánchez‐Ramos +4 more
In a region where enterotoxigenic E. coli was the predominant cause of travelers' diarrhea, loperamide combined with ciprofloxacin was not better than treatment with c iproflOxacin alone, and both regimens were safe.
Annals of Internal MedicineBicozamycin, A Poorly Absorbable Antibiotic, Effectively Treats Travelers' Diarrhea
98 Citations1983Charles D. Ericsson, Herbert L. DuPont +4 more
Treatment failed in significantly fewer patients treated with bicozamycin than those treated with placebo when diarrhea was associated with Shigella, Salmonella or toxigenic E. coli, indicating a need to reevaluate the clinical dictum that nonabsorbable antibiotics are ineffective against invasive enteropathogens.
DigestionRifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers’ Diarrhea
94 Citations1998Herbert L. DuPont, Charles D. Ericsson +6 more
Rifaximin shortened the duration of travelers’ diarrhea compared with TMP/SMX and 2 earlier studied placebo-treated groups, and a poorly absorbed drug if effective in treating bacterial diarrhea has pharmacologic and safety advantages over the existing drugs.
The Journal of Infectious DiseasesNatural History of Enteroaggregative and Enterotoxigenic<i>Escherichia coli</i>Infection among US Travelers to Guadalajara, Mexico
78 Citations2002Javier A. Adachi, Charles D. Ericsson +4 more
Plasmid DNA analysis showed a high degree of heterogeneity among EAEC isolates, and Symptomatic EAEC infection occurred early after arrival in Guadalajara, Mexico, and was as common as ETEC infection.
JAMAOral Aztreonam, A Poorly Absorbed Yet Effective Therapy for Bacterial Diarrhea in US Travelers to Mexico
70 Citations1992Herbert L. DuPont
Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.
Journal of ChemotherapyIntestinal Protozoa in HIV-Infected Patients: Effect of Rifaximin in<i>Cryptosporidium parvum</i>and<i>Blastocystis hominis</i>Infections
59 Citations1999M. Amenta, E.R. Dalle Nogare +6 more
Treatment with rifaximin was efficacious in resolving the clinical symptoms and clearing protozoan infections in HIV-1 infected patients with CD4 > or = 200/mm3, who presented enteric and systemic symptoms due to Criptosporidium or Blastocystis associated with enteropathogenic bacteria.
Clinical Infectious DiseasesEvaluation of New Anti-Infective Drugs for the Treatment of Acute Infectious Diarrhea
36 Citations1992Herbert L. DuPont, Michael Cooperstock +3 more
This guideline includes diarrhea causing infantile mortality in which a bacterial pathogen is recovered and for which oral rehydration therapy is an important component of care as well as traveler's diarrhea (with or without recovery of a pathogen).
Journal of Travel MedicineOptimal Dosing of Ofloxacin with Loperamide in the Treatment of Non-Dysenteric Travelers’ Diarrhea
35 Citations2006Charles D. Ericsson, Herbert L. DuPont +1 more
JAMAOral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico
19 Citations1992Herbert L. DuPont
Journal of Clinical MicrobiologyTest-of-cure stool cultures for traveler's diarrhea
18 Citations1988Charles D. Ericsson, Herbert L. DuPont +4 more
Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated and placebo-treated groups.